Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycine transporter 1 (GlyT1), encoded by the SLC6A9 gene, is a sodium- and chloride-dependent membrane protein responsible for the reuptake of glycine from the synaptic cleft. It plays a crucial role in regulating glycine concentrations at inhibitory glycinergic synapses and modulating excitatory neurotransmission via NMDA receptors. Selective inhibitors that block GlyT1 increase extracellular synaptic glycine concentration—this potentiates NMDA receptor function. Mutations in SLC6A9 cause "glycine encephalopathy with normal serum glycine" (OMIM #617301), also known as GlyT1 encephalopathy.
Inhibition of GlyT1 leading to increased synaptic glycine concentration and potentiation of NMDA receptor function.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycine Transporter 1 (GlyT1).